<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2d1 20170631//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="article" dtd-version="1.2d1" specific-use="production" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">BIORXIV</journal-id>
<journal-title-group>
<journal-title>bioRxiv</journal-title>
<abbrev-journal-title abbrev-type="publisher">bioRxiv</abbrev-journal-title>
</journal-title-group>
<publisher>
<publisher-name>Cold Spring Harbor Laboratory</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1101/428284</article-id>
<article-version>1.1</article-version>
<article-categories>
<subj-group subj-group-type="author-type">
<subject>Regular Article</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>New Results</subject>
</subj-group>
<subj-group subj-group-type="hwp-journal-coll">
<subject>Microbiology</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Leveraging the effects of chloroquine on resistant malaria parasites for combination therapies</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Untaroiu</surname>
<given-names>Ana M.</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="author-notes" rid="n1">&#x005E;</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Carey</surname>
<given-names>Maureen A.</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="author-notes" rid="n1">&#x005E;</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Guler</surname>
<given-names>Jennifer L.</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="corresp" rid="cor1">&#x002A;</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Papin</surname>
<given-names>Jason A.</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="corresp" rid="cor1">&#x002A;</xref>
</contrib>
<aff id="a1"><label>1</label><institution>Department of Biomedical Engineering, University of Virginia</institution>, Charlottesville, VA, <country>USA</country></aff>
<aff id="a2"><label>2</label><institution>Department of Microbiology, Immunology, and Cancer Biology, University of Virginia</institution>, Charlottesville, VA, <country>USA</country></aff>
<aff id="a3"><label>3</label><institution>Department of Biology, University of Virginia</institution>, Charlottesville, VA, <country>USA</country></aff>
</contrib-group>
<author-notes>
<fn fn-type="other" id="n1"><label>&#x005E;</label><p>Co-first authors</p></fn>
<corresp id="cor1"><label>&#x002A;</label>Co-corresponding authors: <email>jlg5fw@virginia.edu</email>, <email>papin@virginia.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub"><year>2018</year></pub-date>
<elocation-id>428284</elocation-id>
<history>
<date date-type="received">
<day>26</day>
<month>9</month>
<year>2018</year>
</date>
<date date-type="rev-recd">
<day>26</day>
<month>9</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>26</day>
<month>9</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>&#x00A9; 2018, Posted by Cold Spring Harbor Laboratory</copyright-statement>
<copyright-year>2018</copyright-year>
<license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link></license-p></license>
</permissions>
<self-uri xlink:href="428284.pdf" content-type="pdf" xlink:role="full-text"/>
<abstract>
<title>Abstract</title>
<p>Malaria is a major global health problem, with the <italic>Plasmodium falciparum</italic> protozoan parasite causing the most severe form of the disease. Prevalence of drug-resistant <italic>P. falciparum</italic> highlights the need to understand the biology of resistance and to identify novel combination therapies that are effective against resistant parasites. Resistance has compromised the therapeutic use of many antimalarial drugs, including chloroquine, and limited our ability to treat malaria across the world. Fortunately, chloroquine resistance comes at a fitness cost to the parasite; this can be leveraged in developing combination therapies or to reinstate use of chloroquine. To understand biological changes induced by chloroquine treatment, we compared transcriptomics data from chloroquine-resistant parasites in the presence or absence of the drug. Using both linear models and a genome-scale metabolic network reconstruction of the parasite to interpret the expression data, we identified targetable pathways in resistant parasites. This study identified an increased importance of lipid synthesis, glutathione production/cycling, isoprenoids biosynthesis, and folate metabolism in response to chloroquine. We identified potential drug targets for chloroquine combination therapies. Significantly, our analysis suggests that the combination of chloroquine and sulfadoxine-pyrimethamine or fosmidomycin may be more effective against chloroquine-resistant parasites than either drug alone; further studies will explore the use of these drugs as chloroquine resistance blockers. Additional metabolic weaknesses were found in glutathione generation and lipid synthesis during chloroquine treatment. These processes could be targeted with novel inhibitors to reduce parasite growth and reduce the burden of malaria infections. Thus, we identified metabolic weaknesses of chloroquine-resistant parasites and propose targeted chloroquine combination therapies.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keywords</title>
<kwd>Malaria</kwd>
<kwd>combination therapies</kwd>
<kwd>chloroquine</kwd>
<kwd>metabolic modeling</kwd>
</kwd-group>
<counts>
<page-count count="31"/>
</counts>
</article-meta>
<def-list><title>List of abbreviations</title>
<def-item><term>CQ</term><def><p>chloroquine</p></def></def-item>
<def-item><term>DEG</term><def><p>differentially expressed gene</p></def></def-item>
<def-item><term>FBA</term><def><p>flux balance analysis</p></def></def-item>
<def-item><term>FC</term><def><p>fold change</p></def></def-item>
<def-item><term>FDR</term><def><p>false-discovery rate</p></def></def-item>
<def-item><term>MADE</term><def><p>Metabolic Adjustment for Differential Expression</p></def></def-item>
</def-list>
</front>
<body>
<sec id="s1"><title>Background</title>
<p>There are approximately 3.2 billion people at risk of malaria infection worldwide and the malaria parasites cause half a million deaths annually (<xref ref-type="bibr" rid="c1">1</xref>). Given the lack of a broadly effective vaccine, antimalarial drugs and protection from mosquito bites are essential in the control of malaria (<xref ref-type="bibr" rid="c2">2</xref>). The most lethal species of the protozoan parasite that causes malaria, <italic>Plasmodium falciparum</italic>, has acquired resistance to every antimalarial drug on the market (<xref ref-type="bibr" rid="c3">3</xref>,<xref ref-type="bibr" rid="c4">4</xref>). Since the development of novel antimalarials is slow, there is a need for combination therapies to target resistant parasites.</p>
<p>First introduced in 1934, chloroquine was a front-line antimalarial until the late 1950s when its heavy usage led to emergence of resistant <italic>P. falciparum</italic> strains near the Cambodia-Thailand border (<xref ref-type="bibr" rid="c5">5</xref>). Chloroquine resistance has now been confirmed in over 40 countries, making resistance to this drug a global concern (<xref ref-type="bibr" rid="c5">5</xref>). The mechanism of action of chloroquine is well studied. In intraerythrocytic trophozoite parasites, the drug blocks detoxification of heme, a byproduct of hemoglobin degradation (<xref ref-type="bibr" rid="c6">6</xref>). During the asexual intraerythrocytic-stages, the parasite imports host cell hemoglobin into its food vacuole (<xref ref-type="bibr" rid="c7">7</xref>,<xref ref-type="bibr" rid="c8">8</xref>). Proteases in the food vacuole degrade hemoglobin into free amino acids which are utilized in various growth processes (<xref ref-type="bibr" rid="c9">9</xref>). Heme is released during hemoglobin digestion and is essential for parasite growth as a cofactor for cytochromes in the parasite&#x2019;s electron transport chain (<xref ref-type="bibr" rid="c10">10</xref>,<xref ref-type="bibr" rid="c11">11</xref>); however, elevated levels of intracellular heme can lead to cellular damage: oxidation of proteins, inhibition of proteases, and damage or lysis of membranes (<xref ref-type="bibr" rid="c12">12</xref>&#x2013;<xref ref-type="bibr" rid="c14">14</xref>). Heme released from hemoglobin is detoxified through three known mechanisms: [1] polymerization into hemozoin crystals, [2] detoxification through interactions with hydrogen peroxide in the food vacuole, and [3] a glutathione-mediated degradation process in the cytoplasm (<xref ref-type="bibr" rid="c7">7</xref>,<xref ref-type="bibr" rid="c13">13</xref>,<xref ref-type="bibr" rid="c15">15</xref>,<xref ref-type="bibr" rid="c16">16</xref>). Chloroquine chemically binds to heme and the growing ends of hemozoin crystals, preventing crystallization-mediated heme detoxification (<xref ref-type="bibr" rid="c17">17</xref>,<xref ref-type="bibr" rid="c18">18</xref>).</p>
<p>Chloroquine-resistant parasites are able to export chloroquine (<xref ref-type="bibr" rid="c19">19</xref>), which reduces the accessibility of chloroquine to its heme and hemozoin targets (<xref ref-type="bibr" rid="c20">20</xref>,<xref ref-type="bibr" rid="c21">21</xref>). This resistance phenotype is mediated by mutations in the <italic>P. falciparum</italic> chloroquine resistance transporter <italic>(pfcrt)</italic> gene that results in the removal of drug from its functional site, the food vacuole (<xref ref-type="bibr" rid="c22">22</xref>,<xref ref-type="bibr" rid="c23">23</xref>). Numerous mutations are associated with chloroquine resistance, depending on the genetic background, and result in varying degrees of resistance (<xref ref-type="bibr" rid="c22">22</xref>,<xref ref-type="bibr" rid="c24">24</xref>&#x2013;<xref ref-type="bibr" rid="c26">26</xref>). However, the substitution of lysine to threonine at position 76 in <italic>pfcrt</italic> is found in all <italic>in vitro</italic> chloroquine-resistant parasites (<xref ref-type="bibr" rid="c27">27</xref>,<xref ref-type="bibr" rid="c28">28</xref>).</p>
<p>Although chloroquine resistance is a well-studied case of antimalarial resistance, the mechanistic details remain poorly characterized. Studies on hemozoin formation estimate that only a third of heme released from hemoglobin is sequestered into hemozoin, suggesting a majority of heme is broken down through alternative, less well-characterized mechanisms, like peroxidative and glutathione degradation (<xref ref-type="bibr" rid="c16">16</xref>,<xref ref-type="bibr" rid="c29">29</xref>). Additional investigations are needed to understand the interplay between these mechanisms, which may become important in situations where resistant parasites are exposed to chloroquine. This situation is a greater possibility today, as some malaria endemic countries consider reintroducing chloroquine into their treatment regimens. Chloroquine resistance confers a fitness cost; thus, resistance alleles do not become fixed and decline in prevalence after chloroquine use is discontinued (<xref ref-type="bibr" rid="c30">30</xref>,<xref ref-type="bibr" rid="c31">31</xref>). As a result, clinical trials have confirmed that reintroduction of chloroquine is highly efficacious (<xref ref-type="bibr" rid="c32">32</xref>,<xref ref-type="bibr" rid="c33">33</xref>). Based on these findings, a reintroduction of chloroquine as a part of combination therapies may be an effective treatment strategy.</p>
<p>This study investigates the effects of chloroquine on chloroquine-resistant parasites to identify partner drugs that could be used in combination therapies to accelerate the reintroduction of chloroquine. We integrated the transcriptomics data from chloroquine-resistant parasites with or without chloroquine treatment (<xref ref-type="bibr" rid="c34">34</xref>) into a <italic>P. falciparum</italic> genome-scale metabolic network reconstruction to predict large-scale metabolic changes initiated by drug treatment, as we previously performed to study artemisinin resistance (<xref ref-type="bibr" rid="c35">35</xref>). We identified shifts in metabolic flux and clinically available inhibitors that may partner well with chloroquine to target chloroquine resistant parasites.</p></sec>
<sec id="s2"><title>Methods</title>
<sec id="s2a"><title>Differential Gene Analysis</title>
<p>Expression data from <italic>in vitro</italic> K1 parasites untreated or treated with EC<sub>50</sub> concentrations of chloroquine for 4hr and 24hrs were used to investigate the transcriptional effects of chloroquine treatment (normalized expression data obtained via GEO accession number: GSE31109) (<xref ref-type="bibr" rid="c34">34</xref>). Exposure for 4 and 24 hours were defined as short and long-term treatment, respectively. Probes with missing expression values were set equal to the lowest expression value across all replicates for that probe (<xref ref-type="bibr" rid="c35">35</xref>). Mean or median values across replicates were not used to replace missing expression values to avoid skewing the data with outliers. Genes with multiple probes were filtered from the data to ensure each gene corresponds to only one microarray probe. For repeating probes, only expression data from the probe with the largest variance across all replicates were retained. Means from repeating probes were not used to prevent averaging true signal with background noise. Probes with missing gene IDs were removed from the dataset.</p>
<p>The R package limma was used to conduct differential gene expression analysis <bold>(<xref ref-type="fig" rid="fig1">Figure 1</xref>)</bold>. Limma uses linear models to fit a data set and empirical Bayes statistical methods to determine variability and log-fold changes in gene expression (<xref ref-type="bibr" rid="c36">36</xref>). Significance values from this analysis (p-values) were modified using false discovery rate (FDR) correction in order to control for the parallel manner of comparing genes using limma, instead of testing genes in isolation. Differentially expressed genes were characterized as genes having a fold change (FC) greater than 2 or less than 0.5 and a FDR-adjusted p-value less than 0.05.</p>
<fig id="fig1" position="float" orientation="portrait" fig-type="figure">
<label>Figure 1:</label>
<caption><title>Overview of Computational Approach.</title>
<p>The R package limma was used to find differentially expressed genes (left square). Metabolic Adjustment for Differential Expression (MADE) algorithm was used to produce the condition-specific models (right 3 circles). Flux balance analysis (FBA) and simulated reaction deletions predicted drug targets for chloroquine-treated parasites. CQ &#x003D; Chloroquine.</p></caption>
<graphic xlink:href="428284_fig1.tif"/>
</fig></sec>
<sec id="s2b"><title>Model Curation</title>
<p>Additional reactions were included into the <italic>P. falciparum</italic> model based on supporting experimental evidence (<xref ref-type="bibr" rid="c35">35</xref>). More specifically, hydrogen peroxide was incorporated as a byproduct of hemoglobin digestion based on studies of the chemical steps in hemoglobin breakdown (<xref ref-type="bibr" rid="c37">37</xref>). Reactions for heme degradation via glutathione and hydrogen peroxide were incorporated based on supporting literature (<xref ref-type="bibr" rid="c38">38</xref>,<xref ref-type="bibr" rid="c39">39</xref>). See <bold><xref ref-type="table" rid="tblS1">Supplemental Table 1</xref></bold> for modified reactions.</p></sec>
<sec id="s2c"><title>Condition-specific Model Generation</title>
<p>Condition-specific models were produced by integrating gene IDs with corresponding log FCs and FDR-adjusted p-values from the 4 and 24 hour treatment conditions into a curated version (see above) of the intraerythrocytic-stage <italic>P. falciparum</italic> genome-scale metabolic network reconstruction (<xref ref-type="bibr" rid="c35">35</xref>) (<bold><xref ref-type="fig" rid="fig1">Figure 1</xref></bold>). Data integration was conducted by using the Metabolic Adjustment for Differential Expression (MADE) algorithm; this algorithm accounts for the expression state of a gene with a weighted consideration of the statistical significance of the gene expression changes (<xref ref-type="bibr" rid="c40">40</xref>). Condition-specific models were generated for each condition (4hr chloroquine-treated, 24hr chloroquine-treated, and untreated) using varying growth thresholds (30 &#x2013; 80&#x0025;). This threshold represents the fraction of metabolic objective required for the output condition-specific model. We explored the effects of this threshold on condition-specific models to find minor differences in results. This paper reports common results across all models.</p></sec>
<sec id="s2d"><title>Reaction Essentiality Predictions and Flux Analysis</title>
<p>Essential reactions for each condition-specific model were generated by sequentially removing single reactions and testing the modified model for growth using flux balance analysis (<xref ref-type="bibr" rid="c41">41</xref>) (<bold><xref ref-type="fig" rid="fig1">Figure 1</xref></bold>). Reactions were delineated as essential when the removal of the reaction from the model resulted in a decrease of the growth rate by 60&#x0025; or more compared to the untreated model. This growth rate threshold was chosen to avoid a too conservative definition of essentiality, but to also ensure a significant growth defect. Existing algorithms in the COBRA toolbox were used to calculate ranges of possible flux levels through reactions in the condition-specific models (<xref ref-type="bibr" rid="c42">42</xref>,<xref ref-type="bibr" rid="c43">43</xref>). Generation of condition-specific models, reaction essentiality, and flux analysis were conducted using MATLAB vR2014a, COBRA Toolbox v3.0, and Gurobi 6.5.2 solver.</p></sec>
<sec id="s2e"><title>Enrichment Analysis</title>
<p>The enrichment of metabolic subsystems among essential reactions were investigated. The purpose of this analysis is to determine whether a certain subsystem appears to a greater or lesser extent than expected by chance. Corresponding metabolic subsystems for genes and reactions were derived from the genome-scale metabolic model used in this study (<xref ref-type="bibr" rid="c35">35</xref>). We tested for enrichment of subsystems among essential genes with reference to the unconstrained model using a Fisher&#x2019;s exact test. Significant subsystems were defined as having a FDR-adjusted p-value less than 0.05. RStudio v3.3.0 was used for the differential gene and enrichment analysis.</p></sec></sec>
<sec id="s3"><title>Results</title>
<sec id="s3a"><title>Resistant parasites respond to chloroquine pressure with moderate but statistically significant gene down-regulation</title>
<p>Since this analysis was not performed in the original study (<xref ref-type="bibr" rid="c34">34</xref>), differentially expressed genes (DEGs) were identified for both short and long-term treatment relative to untreated trophozoite expression. The majority of genes do not show a significant change in expression in response to chloroquine treatment (genes represented by points in black, <bold><xref ref-type="fig" rid="fig2">Figure 2</xref></bold>). Out of a total of 5,121 genes, there were 97 and 166 differentially expressed genes (DEGs) in short- and long-term treatment conditions, respectively (represented by points in red, <bold><xref ref-type="fig" rid="fig2">Figure 2</xref></bold>). In both conditions, more genes were significantly down-regulated than up-regulated in response to chloroquine treatment (95.9&#x0025; for short-term and 83.1&#x0025; for long-term treatment, fold change less than 0.5, <bold><xref ref-type="table" rid="tblS2">Suppl. Table 2</xref></bold>). Up-regulated genes showed very moderate over-expression (fold change between 2 and 2.5) and included one metabolic gene (<bold><xref ref-type="table" rid="tblS3">Suppl. Table 3</xref></bold>). No evidence was found to suggest these DEGs are directly involved in chloroquine treatment or resistance.</p>
<fig id="fig2" position="float" orientation="portrait" fig-type="figure">
<label>Figure 2:</label>
<caption><title>Resistant Parasites Respond to Drug by Downregulating Expression.</title>
<p>FDR-adjusted p-values and fold changes (FC, reported as log values) for genes during (A) short-term treatment and (B) long-term treatment with chloroquine. Adjusted p-values represent the significance level of changes in expression. Fold change quantifies the variation in the gene expression relative to untreated resistant parasite expression. DEGs &#x003D; differentially expressed genes.</p></caption>
<graphic xlink:href="428284_fig2.tif"/>
</fig></sec>
<sec id="s3b"><title>Identifying metabolic weakness of chloroquine-treated resistant parasites using metabolic modeling</title>
<p>In order to understand the system-wide context for these gene expression changes, we integrated transcriptomics data into a genome-scale metabolic network reconstruction of intraerythrocytic-stage <italic>P. falciparum</italic> to generate three condition-specific models (untreated, short- and long-term chloroquine treatment). We then predicted reactions essential for parasite growth. One hundred and sixty-four metabolic reactions (out of 1197) are essential in all three models (<bold><xref ref-type="fig" rid="fig3">Figure 3A</xref></bold>, center); these reactions represent core metabolic pathways of the parasite.</p>
<fig id="fig3" position="float" orientation="portrait" fig-type="figure">
<label>Figure 3.</label>
<caption><title>Chloroquine-treated parasites have new metabolic weaknesses.</title>
<p>(<bold>A</bold>) Comparison of essential reactions in the three condition-specific models (one for each condition: short-term and long-term chloroquine treatment, as well as the untreated condition). (<bold>B</bold>) Illustration of common essentiality predictions (underlined in A) between the drug-treatment models, including inositol phosphate metabolism and glutathione import are represented. These enzymes could be targeted in these resistant parasites in combination with chloroquine; resultant combination therapies would specifically target resistant parasites during chloroquine treatment, not wild-type parasites or single-drug treatment. Red region depicts the host red blood cell and grey is the parasite&#x2019;s cytoplasm.</p></caption>
<graphic xlink:href="428284_fig3.tif"/>
</fig>
<p>Reactions that become essential during chloroquine treatment highlight weak points in the metabolic network and can be exploited as drug targets in chloroquine-resistant parasites. We found 210 and 208 essential metabolic reactions in short- and long-term treatment, respectively. Thirty-two were shared between the two conditions <bold>(<xref ref-type="table" rid="tblS5">Suppl. Table 5</xref>, <xref ref-type="fig" rid="fig3">Figure 3</xref></bold>); fifteen of these are involved in phosphatidylethanolamine and phosphatidylserine metabolism, seven in phospholipid utilization, and one in the import of reduced glutathione <bold>(</bold>examples summarized in <bold><xref ref-type="fig" rid="fig3">Figure 3B</xref></bold>; <bold><xref ref-type="table" rid="tblS5">Suppl. Table 5</xref></bold>). When we performed subsystem enrichment on the essential reactions, the following subsystems were over-represented: phosphatidylethanolamine and phosphatidylserine metabolism (p-value &#x003D; 4.84E-6), tRNA synthesis (p-value &#x003D; 0.024), and phospholipid utilization (p-value &#x003D; 0.037). Reactions involved in transport and lipid metabolism were under-represented in chloroquine treated models (p-value &#x003D; 0.0061 and 2.51E-8, respectively).</p>
<p>Fourteen reactions are essential in only the short-term treatment model <bold>(<xref ref-type="fig" rid="fig3">Figure 3A</xref></bold> in blue, <bold><xref ref-type="table" rid="tblS6">Suppl. Table 6</xref></bold>). Of these essential reactions, five reactions are involved in the <italic>de novo</italic> synthesis of thiamine diphosphate, the active form of vitamin B1 <bold>(<xref ref-type="fig" rid="fig4">Figure 4</xref></bold> in white<bold>)</bold>. Eight reactions were uniquely essential in the long-term treatment model <bold>(<xref ref-type="fig" rid="fig3">Figure 3A</xref></bold> in green, <bold><xref ref-type="table" rid="tblS7">Suppl. Table 7</xref>)</bold>, notably the conversion of chorismate into 4-aminobenzoate for folate metabolism is essential <bold>(<xref ref-type="fig" rid="fig5">Figure 5</xref></bold> in black<bold>)</bold>.</p>
<fig id="fig4" position="float" orientation="portrait" fig-type="figure">
<label>Figure 4.</label>
<caption><title>Increased Flux in Isoprenoids Metabolism in Response to Chloroquine.</title>
<p>Illustration of isoprenoid metabolism reactions showing increases in flux levels in both chloroquine-treated models versus untreated models (represented in grey). 1-deoxy-D-xylulose-5-phosphate synthase utilizes thiamine diphosphate as a cofactor (marked by dotted arrow). We also predict a shift in thiamine diphosphate production, where the <italic>de novo</italic> synthesis pathway (shown in white) and the import pathway (shown in solid black) is used during short- and long-term treatment, respectively. Pharmacologic inhibitors target isoprenoid metabolism (fosmidomycin, indicated in red). Connectivity to other metabolic pathways are shown (dotted lines).</p></caption>
<graphic xlink:href="428284_fig4.tif"/>
</fig>
<fig id="fig5" position="float" orientation="portrait" fig-type="figure">
<label>Figure 5.</label>
<caption><title>Increased Flux in Folate Metabolism in Response to Chloroquine.</title>
<p>Illustration of folate metabolism reactions showing increases in flux levels in both chloroquine-treated models versus untreated models. We predict a shift in 4-aminobenzoate acquisition between short- and long-term chloroquine treatment, and elevated flux through all downstream steps of folate metabolism. Clinically available drugs target this pathway (sulfadoxine and pyrimethamine, indicated in red). Both enzymes targeted by these antimalarials (dihydropteroate synthase and dihydrofolate reductase) carry increased flux in both models of short- and long-term chloroquine treatment. Connectivity to other metabolic pathways are shown (dotted lines).</p></caption>
<graphic xlink:href="428284_fig5.tif"/>
</fig>
<p>We explored why thiamine diphosphate synthesis was essential only in the short-term treatment model. <italic>P. falciparum</italic> has an alternate route for thiamine diphosphate production (termed &#x2018;import pathway&#x2019;, <bold><xref ref-type="fig" rid="fig4">Figure 4</xref></bold>), where thiamine is imported into the parasite&#x2019;s cytoplasm and phosphorylated by thiamine diphosphokinase to form thiamine diphosphate. For the untreated and long-term treatment models, only the import pathway is active. For the short-term treatment model, only the <italic>de novo</italic> synthesis pathway has activity. These results suggest a switch in thiamine diphosphate production in early stages of drug treatment.</p>
<p>Six enzymes are known to utilize thiamine diphosphate (also called thiamine pyrophosphate) as a cofactor in <italic>P. falciparum</italic> (44&#x2013;48). Flux levels of these reactions predicted from flux balance analysis were investigated to understand thiamine diphosphate usage and essentiality. Flux balance analysis simulates steady-state flux values through the network&#x2019;s reactions and predicts the reactions needed to maximize the objective function, which was selected as the biomass equation; thus, this analysis predicts reactions needed for growth. Four of these thiamine diphosphate dependent enzymes (pyruvate dehydrogenase, 2-oxoglutarate dehydrogenase, 3-methyl-2-oxobutanoate dehydrogenase, and branched-chain-alpha-keto-acid dehydrogenase) are predicted to carry no flux in treated and untreated parasites. In response to drug treatment, flux changes through two thiamine diphosphate-dependent reactions: flux through the reaction catalyzed by 1-deoxy-D-xylulose phosphate synthase increases (in isoprenoids metabolism) and flux through the reaction catalyzed by transketolase decreases (in pentose phosphate pathway). Flux of the other reactions in isoprenoids metabolism are also consistently greater in response to chloroquine treatment <bold>(<xref ref-type="fig" rid="fig4">Figure 4</xref></bold> in grey<bold>; <xref ref-type="table" rid="tblS8">Suppl. Table 8</xref>)</bold>. Compared to untreated models, short- and long-term treatment show a 62 &#x2013; 83&#x0025; and 24&#x0025; increase in flux, respectively.</p>
<p>To next focus on the reactions essential in only the long-term treatment model, we explored the utilization of chorismate, a precursor of folate. During long-term chloroquine treatment, synthesis of 4-aminobenzoate from chorismate is used, rather than importing 4-aminobenzoate from the host cell <bold>(<xref ref-type="fig" rid="fig5">Figure 5</xref>)</bold>. Thus, the conversion of chorismate into 4-aminobenzoate is essential. In contrast, short-term chloroquine-treated parasites predominately rely on membrane folate transporters (PfFTl and PfFT2) for 4-aminobenzoate <bold>(<xref ref-type="fig" rid="fig5">Figure 5</xref>)</bold>. Downstream steps in folate metabolism, including dihydropteroate synthase and dihydrofolate reductase, carry a 62.4&#x0025; and 24.2&#x0025; increase in flux during short- and long-term chloroquine treatment, respectively <bold>(<xref ref-type="fig" rid="fig5">Figure 5</xref></bold> in grey; <bold><xref ref-type="table" rid="tblS9">Suppl. Table 9</xref></bold>).</p></sec></sec>
<sec id="s4"><title>Discussion</title>
<p>In this study, we used transcriptomics data to investigate metabolic shifts resulting from chloroquine treatment of resistant parasites. We performed differential expression analysis and integrated expression data into a genome-scale metabolic model to identify targetable weaknesses of chloroquine-treated resistant parasites. Using this approach, we identified metabolic pathways that, if targeted, could be developed as partner drugs for chloroquine combination therapies.</p>
<sec id="s4a"><title>Chloroquine affects resistant parasites</title>
<p>Importantly, we observed a significant down-regulation of genes in response to chloroquine treatment (<bold><xref ref-type="fig" rid="fig2">Figure 2</xref></bold>). This suggests that chloroquine treatment continues to affect the resistant parasite, despite the parasite&#x2019;s resistance to the drug&#x2019;s cytocidal effects. This observation is consistent with growth defects observed in chloroquine-treated resistant parasites (20&#x0025; and 45&#x0025; inhibition after 8 and 48 hours, respectively (<xref ref-type="bibr" rid="c49">49</xref>)). Moreover, the effect of chloroquine is widespread and not just a function of a single gene, as evident by the numerous differentially expressed genes, and the multiple nonspecific resistance alleles (<xref ref-type="bibr" rid="c50">50</xref>,<xref ref-type="bibr" rid="c51">51</xref>). Longer exposure time exacerbates this effect, as illustrated by the increase in DEGs with the 24-hour drug treatment (<bold><xref ref-type="fig" rid="fig2">Figure 2</xref></bold>).</p></sec>
<sec id="s4b"><title>Novel proposed targets against chloroquine-resistant parasites</title>
<p>We propose that resistant parasites are using different metabolic pathways when in the presence of chloroquine because there are treatment-associated essential reactions. Subsystem enrichment of essentiality predictions suggests many shifts in lipid metabolism. The increased importance of phospholipids in both treatment conditions (<xref ref-type="fig" rid="fig3">Figure 3B</xref>) may represent the parasite&#x2019;s attempt to counteract the effects of chloroquine treatment. This response could occur through a number of routes: first, additional lipid species may be required to repair cellular membranes damaged by the build-up of intracellular heme during chloroquine treatment (<xref ref-type="bibr" rid="c14">14</xref>). Second, lipids themselves have been shown to contribute to the detoxification of heme into hemozoin (<xref ref-type="bibr" rid="c52">52</xref>,<xref ref-type="bibr" rid="c53">53</xref>). The demand for lipids for these roles may represent a targetable metabolic weakness of drug-treated chloroquine-resistant parasites.</p>
<p>The transport of glutathione from the extracellular environment into the cytoplasm is predicted to be essential during chloroquine treatment <bold>(<xref ref-type="fig" rid="fig3">Figure 3B</xref>)</bold>. Glutathione is involved in the degradation of non-polymerized heme, in addition to being involved in managing oxidative stress in the parasite (<xref ref-type="bibr" rid="c15">15</xref>). Since these reactions are only essential during chloroquine treatment, this result suggests the activation of these reactions may be a direct result of drug pressure placed on the parasite and the accompanying cellular damage. This result is supported by observed correlations between chloroquine resistance and intracellular glutathione levels (<xref ref-type="bibr" rid="c54">54</xref>&#x2013;<xref ref-type="bibr" rid="c56">56</xref>). The competitive inhibition of glutathione degradation by heme also supports the increased importance of glutathione accumulations to counteract chloroquine pressures (<xref ref-type="bibr" rid="c57">57</xref>). Thus, glutathione is essential in combating the effects of chloroquine and can be considered another metabolic weakness of resistant parasites.</p></sec>
<sec id="s4c"><title>Partner drugs for chloroquine combination therapies</title>
<p>Folate metabolism is needed for DNA synthesis and metabolism of certain amino acids (<xref ref-type="bibr" rid="c52">52</xref>). Interestingly, downstream steps in folate metabolism, including dihydropteroate synthase and dihydrofolate reductase, are predicted to carry more flux during chloroquine treatment <bold>(<xref ref-type="fig" rid="fig5">Figure 5</xref>)</bold>, implying they are necessary for survival or tend to be overexpressed during treatment. This result suggests that this pathway has increased importance under chloroquine treatment and could be targeted in combination therapies. Recent clinical use of such a combination therapy supports this conclusion; chloroquine in combination with inhibitors of dihydrofolate reductase and dihydropteroate synthase (sulfadoxine-pyrimethamine) is effective against chloroquine-resistant parasites (<xref ref-type="bibr" rid="c58">58</xref>&#x2013;<xref ref-type="bibr" rid="c60">60</xref>). Our results suggest that chloroquine-resistant parasites are more susceptible to these drugs than sensitive parasites and our modeling approach provides a mechanistic explanation.</p>
<p>Unique to our study, we predict a novel role for isoprenoids synthesis in chloroquine-resistant parasites. Under chloroquine treatment, there is increased flux through reactions in the non-mevalonate pathway for isoprenoids metabolism (<bold><xref ref-type="fig" rid="fig4">Figure 4</xref></bold>), the only synthesis pathway for isoprenoids in <italic>P. falciparum</italic> (<xref ref-type="bibr" rid="c61">61</xref>,<xref ref-type="bibr" rid="c62">62</xref>). This pathway is thiamine diphosphate-dependent and we also observed a switch in thiamine scavenging to <italic>de novo</italic> synthesis (<bold><xref ref-type="fig" rid="fig4">Figure 4</xref></bold>), highlighting the dynamic state of these pathways. Our computational analysis suggests that chloroquine-resistant parasites have increased susceptibility to non-mevalonate pathway inhibitors, such as fosmidomycin and its derivative, FR-900098 <bold>(<xref ref-type="fig" rid="fig4">Figure 4</xref>)</bold> (<xref ref-type="bibr" rid="c63">63</xref>). This metabolic weakness represents an ideal target since the non-mevalonate pathway is constitutively essential, with increased usage in chloroquine-treated resistant parasites (<xref ref-type="bibr" rid="c64">64</xref>). Fosmidomycin alone is moderately effective against chloroquine-resistant parasites (<xref ref-type="bibr" rid="c65">65</xref>) and there is no additivity between fosmidomycin and chloroquine <italic>in vitro</italic> in a pool of chloroquine-sensitive and resistant parasites (<xref ref-type="bibr" rid="c66">66</xref>). Thus, we propose that these parasites are even more susceptible to fosmidomycin while under chloroquine treatment. Thus, we have identified a novel combination therapy involving readily available antimalarials that may inhibit the growth of chloroquine-resistant parasites.</p></sec></sec>
<sec id="s5"><title>Conclusions</title>
<p>The fitness cost associated with chloroquine resistance means that once drug pressure is removed, sensitive parasites again become prominent in the population. Due to its low cost and easy access in malaria endemic countries, chloroquine use is being considered in areas where the return to sensitivity has been confirmed. However, we must be deliberate about how this drug is reinstated to avoid the rapid return of resistant parasites. Thus, we identified potential drug targets for chloroquine combination therapies, using metabolic modeling of resistant parasites under chloroquine treatment. Significantly, we identified that the combination of chloroquine with sulfadoxine-pyrimethamine or fosmidomycin may be more effective against chloroquine-resistant parasites than either drug alone; further studies will explore the use of these drugs as chloroquine resistance blockers. Additional metabolic weaknesses were found in glutathione generation and lipid synthesis during chloroquine treatment. These processes could be targeted with novel inhibitors to reduce parasite growth, thus reducing the burden of malaria infections.</p></sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="c1"><label>1.</label><mixed-citation publication-type="website"><collab>WHO | World Malaria Report</collab> <year>2015</year> <article-title>[Internet]</article-title>. <source>WHO</source>. [cited 2017 Apr 12]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/malaria/publications/world-malaria-report-2015/report/en/">http://www.who.int/malaria/publications/world-malaria-report-2015/report/en/</ext-link></mixed-citation></ref>
<ref id="c2"><label>2.</label><mixed-citation publication-type="book"><string-name><surname>Russell</surname> <given-names>PK</given-names></string-name>, <string-name><surname>Howson</surname> <given-names>CP</given-names></string-name>. <source>Vaccines Against Malaria: Hope in a Gathering Storm [Internet]</source>. <publisher-name>National Academies Press</publisher-name> (<publisher-loc>US</publisher-loc>); <year>1996</year> [cited 2017 Apr 18]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK231030/">https://www.ncbi.nlm.nih.gov/books/NBK231030/</ext-link></mixed-citation></ref>
<ref id="c3"><label>3.</label><mixed-citation publication-type="journal"><string-name><surname>Chakraborty</surname> <given-names>A</given-names></string-name>. <article-title>Emerging drug resistance in Plasmodium falciparum: A review of well-characterized drug targets for novel antimalarial chemotherapy</article-title>. <source>Asian Pac J Trop Dis</source>. <year>2016</year> Jul 1;<volume>6</volume>(<issue>7</issue>):<fpage>581</fpage>&#x2013;<lpage>8</lpage>.</mixed-citation></ref>
<ref id="c4"><label>4.</label><mixed-citation publication-type="journal"><string-name><surname>Cowman</surname> <given-names>AF</given-names></string-name>, <string-name><surname>Healer</surname> <given-names>J</given-names></string-name>, <string-name><surname>Marapana</surname> <given-names>D</given-names></string-name>, <string-name><surname>Marsh</surname> <given-names>K</given-names></string-name>. <article-title>Malaria: Biology and Disease</article-title>. <source>Cell</source>. <year>2016</year> Oct 20;<volume>167</volume>(<issue>3</issue>):<fpage>610</fpage>&#x2013;<lpage>24</lpage>.</mixed-citation></ref>
<ref id="c5"><label>5.</label><mixed-citation publication-type="journal"><string-name><surname>Payne</surname> <given-names>D</given-names></string-name>. <article-title>Spread of chloroquine resistance in Plasmodium falciparum</article-title>. <source>Parasitol Today Pers Ed</source>. <year>1987</year> Aug;<volume>3</volume>(<issue>8</issue>):<fpage>241</fpage>&#x2013;<lpage>6</lpage>.</mixed-citation></ref>
<ref id="c6"><label>6.</label><mixed-citation publication-type="journal"><string-name><surname>Chou</surname> <given-names>AC</given-names></string-name>, <string-name><surname>Chevli</surname> <given-names>R</given-names></string-name>, <string-name><surname>Fitch</surname> <given-names>CD</given-names></string-name>. <article-title>Ferriprotoporphyrin IX fulfills the criteria for identification as the chloroquine receptor of malaria parasites</article-title>. <source>Biochemistry</source>. <year>1980</year> Apr 15;<volume>19</volume>(<issue>8</issue>): <fpage>1543</fpage>&#x2013;<lpage>9</lpage>.</mixed-citation></ref>
<ref id="c7"><label>7.</label><mixed-citation publication-type="journal"><string-name><surname>Francis</surname> <given-names>SE</given-names></string-name>, <string-name><surname>Sullivan</surname> <given-names>DJ</given-names></string-name>, <string-name><surname>Goldberg</surname> <given-names>DE</given-names></string-name>. <article-title>Hemoglobin metabolism in the malaria parasite Plasmodium falciparum</article-title>. <source>Annu Rev Microbiol</source>. <year>1997</year>;<volume>51</volume>:<fpage>97</fpage>&#x2013;<lpage>123</lpage>.</mixed-citation></ref>
<ref id="c8"><label>8.</label><mixed-citation publication-type="journal"><string-name><surname>Goldberg</surname> <given-names>DE</given-names></string-name>, <string-name><surname>Slater</surname> <given-names>AF</given-names></string-name>, <string-name><surname>Cerami</surname> <given-names>A</given-names></string-name>, <string-name><surname>Henderson</surname> <given-names>GB</given-names></string-name>. <article-title>Hemoglobin degradation in the malaria parasite Plasmodium falciparum: an ordered process in a unique organelle</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1990</year> Apr;<volume>87</volume>(<issue>8</issue>):<fpage>2931</fpage>&#x2013;<lpage>5</lpage>.</mixed-citation></ref>
<ref id="c9"><label>9.</label><mixed-citation publication-type="journal"><string-name><surname>Goldberg</surname> <given-names>DE</given-names></string-name>, <string-name><surname>Slater</surname> <given-names>AF</given-names></string-name>, <string-name><surname>Beavis</surname> <given-names>R</given-names></string-name>, <string-name><surname>Chait</surname> <given-names>B</given-names></string-name>, <string-name><surname>Cerami</surname> <given-names>A</given-names></string-name>, <string-name><surname>Henderson</surname> <given-names>GB</given-names></string-name>. <article-title>Hemoglobin degradation in the human malaria pathogen Plasmodium falciparum: a catabolic pathway initiated by a specific aspartic protease</article-title>. <source>J Exp Med</source>. <year>1991</year> Apr 1;<volume>173</volume>(<issue>4</issue>): <fpage>961</fpage>&#x2013;<lpage>9</lpage>.</mixed-citation></ref>
<ref id="c10"><label>10.</label><mixed-citation publication-type="journal"><string-name><surname>Fry</surname> <given-names>M</given-names></string-name>, <string-name><surname>Pudney</surname> <given-names>M</given-names></string-name>. <article-title>Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4&#x2019;-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80)</article-title>. <source>Biochem Pharmacol</source>. <year>1992</year> Apr 1;<volume>43</volume>(<issue>7</issue>): <fpage>1545</fpage>&#x2013;<lpage>53</lpage>.</mixed-citation></ref>
<ref id="c11"><label>11.</label><mixed-citation publication-type="journal"><string-name><surname>Srivastava</surname> <given-names>IK</given-names></string-name>, <string-name><surname>Rottenberg</surname> <given-names>H</given-names></string-name>, <string-name><surname>Vaidya</surname> <given-names>AB</given-names></string-name>. <article-title>Atovaquone, a Broad Spectrum Antiparasitic Drug, Collapses Mitochondrial Membrane Potential in a Malarial Parasite</article-title>. <source>J Biol Chem</source>. <year>1997</year> Feb 14;<volume>272</volume>(<issue>7</issue>):<fpage>3961</fpage>&#x2013;<lpage>6</lpage>.</mixed-citation></ref>
<ref id="c12"><label>12.</label><mixed-citation publication-type="journal"><string-name><surname>Francis</surname> <given-names>SE</given-names></string-name>, <string-name><surname>Gluzman</surname> <given-names>IY</given-names></string-name>, <string-name><surname>Oksman</surname> <given-names>A</given-names></string-name>, <string-name><surname>Knickerbocker</surname> <given-names>A</given-names></string-name>, <string-name><surname>Mueller</surname> <given-names>R</given-names></string-name>, <string-name><surname>Bryant</surname> <given-names>ML</given-names></string-name>, <etal>et al.</etal> <article-title>Molecular characterization and inhibition of a Plasmodium falciparum aspartic hemoglobinase</article-title>. <source>EMBO J</source>. <year>1994</year> Jan 15;<volume>13</volume>(<issue>2</issue>):<fpage>306</fpage>&#x2013;<lpage>17</lpage>.</mixed-citation></ref>
<ref id="c13"><label>13.</label><mixed-citation publication-type="journal"><string-name><surname>Sigala</surname> <given-names>PA</given-names></string-name>, <string-name><surname>Goldberg</surname> <given-names>DE</given-names></string-name>. <article-title>The peculiarities and paradoxes of Plasmodium heme metabolism</article-title>. <source>Annu Rev Microbiol</source>. <year>2014</year>;<volume>68</volume>:<fpage>259</fpage>&#x2013;<lpage>78</lpage>.</mixed-citation></ref>
<ref id="c14"><label>14.</label><mixed-citation publication-type="journal"><string-name><surname>Vander Jagt</surname> <given-names>DL</given-names></string-name>, <string-name><surname>Hunsaker</surname> <given-names>LA</given-names></string-name>, <string-name><surname>Campos</surname> <given-names>NM</given-names></string-name>. <article-title>Characterization of a hemoglobin-degrading, low molecular weight protease from Plasmodium falciparum</article-title>. <source>Mol Biochem Parasitol</source>. <year>1986</year> Mar;<volume>18</volume>(<issue>3</issue>):<fpage>389</fpage>&#x2013;<lpage>400</lpage>.</mixed-citation></ref>
<ref id="c15"><label>15.</label><mixed-citation publication-type="journal"><string-name><surname>Zhang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Krugliak</surname> <given-names>M</given-names></string-name>, <string-name><surname>Ginsburg</surname> <given-names>H</given-names></string-name>. <article-title>The fate of ferriprotorphyrin IX in malaria infected erythrocytes in conjunction with the mode of action of antimalarial drugs</article-title>. <source>Mol Biochem Parasitol</source>. <year>1999</year> Mar 15;<volume>99</volume>(<issue>1</issue>): <fpage>129</fpage>&#x2013;<lpage>41</lpage>.</mixed-citation></ref>
<ref id="c16"><label>16.</label><mixed-citation publication-type="journal"><string-name><surname>Loria</surname> <given-names>P</given-names></string-name>, <string-name><surname>Miller</surname> <given-names>S</given-names></string-name>, <string-name><surname>Foley</surname> <given-names>M</given-names></string-name>, <string-name><surname>Tilley</surname> <given-names>L</given-names></string-name>. <article-title>Inhibition of the peroxidative degradation of haem as the basis of action of chloroquine and other quinoline antimalarials</article-title>. <source>Biochem J</source>. <year>1999</year> Apr 15;<volume>339</volume> ( <issue>Pt 2</issue>):<fpage>363</fpage>&#x2013;<lpage>70</lpage>.</mixed-citation></ref>
<ref id="c17"><label>17.</label><mixed-citation publication-type="journal"><string-name><surname>Sullivan</surname> <given-names>DJ</given-names></string-name>, <string-name><surname>Gluzman</surname> <given-names>IY</given-names></string-name>, <string-name><surname>Russell</surname> <given-names>DG</given-names></string-name>, <string-name><surname>Goldberg</surname> <given-names>DE</given-names></string-name>. <article-title>On the molecular mechanism of chloroquine&#x2019;s antimalarial action</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1996</year> Oct 15;<volume>93</volume>(<issue>21</issue>):<fpage>11865</fpage>&#x2013;<lpage>70</lpage>.</mixed-citation></ref>
<ref id="c18"><label>18.</label><mixed-citation publication-type="journal"><string-name><surname>Pagola</surname> <given-names>S</given-names></string-name>, <string-name><surname>Stephens</surname> <given-names>PW</given-names></string-name>, <string-name><surname>Bohle</surname> <given-names>DS</given-names></string-name>, <string-name><surname>Kosar</surname> <given-names>AD</given-names></string-name>, <string-name><surname>Madsen</surname> <given-names>SK</given-names></string-name>. <article-title>The structure of malaria pigment beta-haematin</article-title>. <source>Nature</source>. <year>2000</year> Mar 16;<volume>404</volume>(<issue>6775</issue>):<fpage>307</fpage>&#x2013;<lpage>10</lpage>.</mixed-citation></ref>
<ref id="c19"><label>19.</label><mixed-citation publication-type="journal"><string-name><surname>Fitch</surname> <given-names>CD</given-names></string-name>. <article-title>Plasmodium falciparum in owl monkeys: drug resistance and chloroquine binding capacity</article-title>. <source>Science</source>. <year>1970</year> Jul 17;<volume>169</volume>(<issue>3942</issue>):<fpage>289</fpage>&#x2013;<lpage>90</lpage>.</mixed-citation></ref>
<ref id="c20"><label>20.</label><mixed-citation publication-type="journal"><string-name><surname>Sanchez</surname> <given-names>CP</given-names></string-name>, <string-name><surname>McLean</surname> <given-names>JE</given-names></string-name>, <string-name><surname>Rohrbach</surname> <given-names>P</given-names></string-name>, <string-name><surname>Fidock</surname> <given-names>DA</given-names></string-name>, <string-name><surname>Stein</surname> <given-names>WD</given-names></string-name>, <string-name><surname>Lanzer</surname> <given-names>M</given-names></string-name>. <article-title>Evidence for a pfcrt-Associated Chloroquine Efflux System in the Human Malarial Parasite Plasmodium falciparum</article-title>. <source>Biochemistry</source>. <year>2005</year> Jul 1;<volume>44</volume>(<issue>29</issue>):<fpage>9862</fpage>&#x2013;<lpage>70</lpage>.</mixed-citation></ref>
<ref id="c21"><label>21.</label><mixed-citation publication-type="journal"><string-name><surname>Krogstad</surname> <given-names>DJ</given-names></string-name>, <string-name><surname>Gluzman</surname> <given-names>IY</given-names></string-name>, <string-name><surname>Kyle</surname> <given-names>DE</given-names></string-name>, <string-name><surname>Oduola</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Martin</surname> <given-names>SK</given-names></string-name>, <string-name><surname>Milhous</surname> <given-names>WK</given-names></string-name>, <etal>et al.</etal> <article-title>Efflux of chloroquine from Plasmodium falciparum: mechanism of chloroquine resistance</article-title>. <source>Science</source>. <year>1987</year> Nov 27;<volume>238</volume>(<issue>4831</issue>): <fpage>1283</fpage>&#x2013;<lpage>5</lpage>.</mixed-citation></ref>
<ref id="c22"><label>22.</label><mixed-citation publication-type="journal"><string-name><surname>Fidock</surname> <given-names>DA</given-names></string-name>, <string-name><surname>Nomura</surname> <given-names>T</given-names></string-name>, <string-name><surname>Talley</surname> <given-names>AK</given-names></string-name>, <string-name><surname>Cooper</surname> <given-names>RA</given-names></string-name>, <string-name><surname>Dzekunov</surname> <given-names>SM</given-names></string-name>, <string-name><surname>Ferdig</surname> <given-names>MT</given-names></string-name>, <etal>et al.</etal> <article-title>Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance</article-title>. <source>Mol Cell</source>. <year>2000</year> Oct;<volume>6</volume>(<issue>4</issue>):<fpage>861</fpage>&#x2013;<lpage>71</lpage>.</mixed-citation></ref>
<ref id="c23"><label>23.</label><mixed-citation publication-type="journal"><string-name><surname>Roepe</surname> <given-names>PD</given-names></string-name>. <article-title>PfCRT-mediated drug transport in malarial parasites</article-title>. <source>Biochemistry</source>. <year>2011</year> Jan 18;<volume>50</volume>(<issue>2</issue>): <fpage>163</fpage>&#x2013;<lpage>71</lpage>.</mixed-citation></ref>
<ref id="c24"><label>24.</label><mixed-citation publication-type="journal"><string-name><surname>Martin</surname> <given-names>SK</given-names></string-name>, <string-name><surname>Oduola</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Milhous</surname> <given-names>WK</given-names></string-name>. <article-title>Reversal of chloroquine resistance in Plasmodium falciparum by verapamil</article-title>. <source>Science</source>. <year>1987</year> Feb 20;<volume>235</volume>(<issue>4791</issue>):<fpage>899</fpage>&#x2013;<lpage>901</lpage>.</mixed-citation></ref>
<ref id="c25"><label>25.</label><mixed-citation publication-type="journal"><string-name><surname>Foote</surname> <given-names>SJ</given-names></string-name>, <string-name><surname>Thompson</surname> <given-names>JK</given-names></string-name>, <string-name><surname>Cowman</surname> <given-names>AF</given-names></string-name>, <string-name><surname>Kemp</surname> <given-names>DJ</given-names></string-name>. <article-title>Amplification of the multidrug resistance gene in some chloroquine-resistant isolates of P. falciparum</article-title>. <source>Cell</source>. <year>1989</year> Jun 16;<volume>57</volume>(<issue>6</issue>):<fpage>921</fpage>&#x2013;<lpage>30</lpage>.</mixed-citation></ref>
<ref id="c26"><label>26.</label><mixed-citation publication-type="journal"><string-name><surname>Wilson</surname> <given-names>CM</given-names></string-name>, <string-name><surname>Serrano</surname> <given-names>AE</given-names></string-name>, <string-name><surname>Wasley</surname> <given-names>A</given-names></string-name>, <string-name><surname>Bogenschutz</surname> <given-names>MP</given-names></string-name>, <string-name><surname>Shankar</surname> <given-names>AH</given-names></string-name>, <string-name><surname>Wirth</surname> <given-names>DF</given-names></string-name>. <article-title>Amplification of a gene related to mammalian mdr genes in drug-resistant Plasmodium falciparum</article-title>. <source>Science</source>. <year>1989</year> Jun 9;<volume>244</volume>(<issue>4909</issue>): <fpage>1184</fpage>&#x2013;<lpage>6</lpage>.</mixed-citation></ref>
<ref id="c27"><label>27.</label><mixed-citation publication-type="journal"><string-name><surname>Djimd&#x00E9;</surname> <given-names>A</given-names></string-name>, <string-name><surname>Doumbo</surname> <given-names>OK</given-names></string-name>, <string-name><surname>Cortese</surname> <given-names>JF</given-names></string-name>, <string-name><surname>Kayentao</surname> <given-names>K</given-names></string-name>, <string-name><surname>Doumbo</surname> <given-names>S</given-names></string-name>, <string-name><surname>Diourt&#x00E9;</surname> <given-names>Y</given-names></string-name>, <etal>et al.</etal> <article-title>A molecular marker for chloroquine-resistant falciparum malaria</article-title>. <source>N Engl J Med</source>. <year>2001</year> Jan 25;<volume>344</volume>(<issue>4</issue>):<fpage>257</fpage>&#x2013;<lpage>63</lpage>.</mixed-citation></ref>
<ref id="c28"><label>28.</label><mixed-citation publication-type="journal"><string-name><surname>Wootton</surname> <given-names>JC</given-names></string-name>, <string-name><surname>Feng</surname> <given-names>X</given-names></string-name>, <string-name><surname>Ferdig</surname> <given-names>MT</given-names></string-name>, <string-name><surname>Cooper</surname> <given-names>RA</given-names></string-name>, <string-name><surname>Mu</surname> <given-names>J</given-names></string-name>, <string-name><surname>Baruch</surname> <given-names>DI</given-names></string-name>, <etal>et al.</etal> <article-title>Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum</article-title>. <source>Nature</source>. <year>2002</year> Jul 18;<volume>418</volume>(<issue>6895</issue>):<fpage>320</fpage>&#x2013;<lpage>3</lpage>.</mixed-citation></ref>
<ref id="c29"><label>29.</label><mixed-citation publication-type="journal"><string-name><surname>Nagababu</surname> <given-names>E</given-names></string-name>, <string-name><surname>Chrest</surname> <given-names>FJ</given-names></string-name>, <string-name><surname>Rifkind</surname> <given-names>JM</given-names></string-name>. <article-title>Hydrogen-peroxide-induced heme degradation in red blood cells: the protective roles of catalase and glutathione peroxidase</article-title>. <source>Biochim Biophys Acta BBA - Gen Subj</source>. <year>2003</year> Mar 17;<volume>1620</volume>(<issue>1</issue>):<fpage>211</fpage>&#x2013;<lpage>7</lpage>.</mixed-citation></ref>
<ref id="c30"><label>30.</label><mixed-citation publication-type="journal"><string-name><surname>Kublin</surname> <given-names>JG</given-names></string-name>, <string-name><surname>Cortese</surname> <given-names>JF</given-names></string-name>, <string-name><surname>Njunju</surname> <given-names>EM</given-names></string-name>, <string-name><surname>Mukadam</surname> <given-names>RAG</given-names></string-name>, <string-name><surname>Wirima</surname> <given-names>JJ</given-names></string-name>, <string-name><surname>Kazembe</surname> <given-names>PN</given-names></string-name>, <etal>et al.</etal> <article-title>Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi</article-title>. <source>J Infect Dis</source>. <year>2003</year> Jun 15;<volume>187</volume>(<issue>12</issue>):<fpage>1870</fpage>&#x2013;<lpage>5</lpage>.</mixed-citation></ref>
<ref id="c31"><label>31.</label><mixed-citation publication-type="journal"><string-name><surname>Mita</surname> <given-names>T</given-names></string-name>, <string-name><surname>Kaneko</surname> <given-names>A</given-names></string-name>, <string-name><surname>Lum</surname> <given-names>JK</given-names></string-name>, <string-name><surname>Bwijo</surname> <given-names>B</given-names></string-name>, <string-name><surname>Takechi</surname> <given-names>M</given-names></string-name>, <string-name><surname>Zungu</surname> <given-names>IL</given-names></string-name>, <etal>et al.</etal> <article-title>RECOVERY OF CHLOROQUINE SENSITIVITY AND LOW PREVALENCE OF THE PLASMODIUM FALCIPARUM CHLOROQUINE RESISTANCE TRANSPORTER GENE MUTATION K76T FOLLOWING THE DISCONTINUANCE OF CHLOROQUINE USE IN MALAWI</article-title>. <source>Am J Trop Med Hyg</source>. <year>2003</year> Apr 1;<volume>68</volume>(<issue>4</issue>):<fpage>413</fpage>&#x2013;<lpage>5</lpage>.</mixed-citation></ref>
<ref id="c32"><label>32.</label><mixed-citation publication-type="journal"><string-name><surname>Laufer</surname> <given-names>MK</given-names></string-name>, <string-name><surname>Thesing</surname> <given-names>PC</given-names></string-name>, <string-name><surname>Eddington</surname> <given-names>ND</given-names></string-name>, <string-name><surname>Masonga</surname> <given-names>R</given-names></string-name>, <string-name><surname>Dzinjalamala</surname> <given-names>FK</given-names></string-name>, <string-name><surname>Takala</surname> <given-names>SL</given-names></string-name>, <etal>et al.</etal> <article-title>Return of Chloroquine Antimalarial Efficacy in Malawi</article-title>. <source>N Engl J Med</source>. <year>2006</year> Nov 9;<volume>355</volume>(<issue>19</issue>): <fpage>1959</fpage>&#x2013;<lpage>66</lpage>.</mixed-citation></ref>
<ref id="c33"><label>33.</label><mixed-citation publication-type="journal"><string-name><surname>Laufer</surname> <given-names>MK</given-names></string-name>, <string-name><surname>Thesing</surname> <given-names>PC</given-names></string-name>, <string-name><surname>Dzinjalamala</surname> <given-names>FK</given-names></string-name>, <string-name><surname>Nyirenda</surname> <given-names>OM</given-names></string-name>, <string-name><surname>Masonga</surname> <given-names>R</given-names></string-name>, <string-name><surname>Laurens</surname> <given-names>MB</given-names></string-name>, <etal>et al.</etal> <article-title>A Longitudinal Trial Comparing Chloroquine as Monotherapy or in Combination with Artesunate, Azithromycin or Atovaquone-Proguanil to Treat Malaria</article-title>. <source>PLOS ONE</source>. <year>2012</year> Aug 17;<volume>7</volume>(<issue>8</issue>):<fpage>e42284</fpage>.</mixed-citation></ref>
<ref id="c34"><label>34.</label><mixed-citation publication-type="journal"><string-name><surname>Kritsiriwuthinan</surname> <given-names>K</given-names></string-name>, <string-name><surname>Chaotheing</surname> <given-names>S</given-names></string-name>, <string-name><surname>Shaw</surname> <given-names>PJ</given-names></string-name>, <string-name><surname>Wongsombat</surname> <given-names>C</given-names></string-name>, <string-name><surname>Chavalitshewinkoon-Petmitr</surname> <given-names>P</given-names></string-name>, <string-name><surname>Kamchonwongpaisan</surname> <given-names>S</given-names></string-name>. <article-title>Global gene expression profiling of Plasmodium falciparum in response to the anti-malarial drug pyronaridine</article-title>. <source>Malar J</source>. <year>2011</year> Aug 18;<volume>10</volume>:<fpage>242</fpage>.</mixed-citation></ref>
<ref id="c35"><label>35.</label><mixed-citation publication-type="journal"><string-name><surname>Carey</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Papin</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Guler</surname> <given-names>JL</given-names></string-name>. <article-title>Novel Plasmodium falciparum metabolic network reconstruction identifies shifts associated with clinical antimalarial resistance</article-title>. <source>BMC Genomics</source>. <year>2017</year> Jul 19;<volume>18</volume>(<issue>1</issue>):<fpage>543</fpage>.</mixed-citation></ref>
<ref id="c36"><label>36.</label><mixed-citation publication-type="journal"><string-name><surname>Ritchie</surname> <given-names>ME</given-names></string-name>, <string-name><surname>Phipson</surname> <given-names>B</given-names></string-name>, <string-name><surname>Wu</surname> <given-names>D</given-names></string-name>, <string-name><surname>Hu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Law</surname> <given-names>CW</given-names></string-name>, <string-name><surname>Shi</surname> <given-names>W</given-names></string-name>, <etal>et al.</etal> <article-title>limma powers differential expression analyses for RNA-sequencing and microarray studies</article-title>. <source>Nucleic Acids Res</source>. <year>2015</year> Apr 20;<volume>43</volume>(<issue>7</issue>):<fpage>e47</fpage>.</mixed-citation></ref>
<ref id="c37"><label>37.</label><mixed-citation publication-type="journal"><string-name><surname>Wallace</surname> <given-names>WJ</given-names></string-name>, <string-name><surname>Houtchens</surname> <given-names>RA</given-names></string-name>, <string-name><surname>Maxwell</surname> <given-names>JC</given-names></string-name>, <string-name><surname>Caughey</surname> <given-names>WS</given-names></string-name>. <article-title>Mechanism of autooxidation for hemoglobins and myoglobins. Promotion of superoxide production by protons and anions</article-title>. <source>J Biol Chem</source>. <year>1982</year> May 10;<volume>257</volume>(<issue>9</issue>):<fpage>4966</fpage>&#x2013;<lpage>77</lpage>.</mixed-citation></ref>
<ref id="c38"><label>38.</label><mixed-citation publication-type="journal"><string-name><surname>Atamna</surname> <given-names>H</given-names></string-name>, <string-name><surname>Ginsburg</surname> <given-names>H</given-names></string-name>. <article-title>Heme Degradation in the Presence of Glutathione A PROPOSED MECHANISM TO ACCOUNT FOR THE HIGH LEVELS OF NON-HEME IRON FOUND IN THE MEMBRANES OF HEMOGLOBINOPATHIC RED BLOOD CELLS</article-title>. <source>J Biol Chem</source>. <year>1995</year> Oct 20;<volume>270</volume>(<issue>42</issue>): <fpage>24876</fpage>&#x2013;<lpage>83</lpage>.</mixed-citation></ref>
<ref id="c39"><label>39.</label><mixed-citation publication-type="journal"><string-name><surname>Brown</surname> <given-names>SB</given-names></string-name>, <string-name><surname>Hatzikonstantinou</surname> <given-names>H</given-names></string-name>, <string-name><surname>Herries</surname> <given-names>DG</given-names></string-name>. <article-title>The role of peroxide in haem degradation. A study of the oxidation of ferrihaems by hydrogen peroxide</article-title>. <source>Biochem J</source>. <year>1978</year> Sep 15;<volume>174</volume>(<issue>3</issue>):<fpage>901</fpage>&#x2013;<lpage>7</lpage>.</mixed-citation></ref>
<ref id="c40"><label>40.</label><mixed-citation publication-type="journal"><string-name><surname>Jensen</surname> <given-names>PA</given-names></string-name>, <string-name><surname>Papin</surname> <given-names>JA</given-names></string-name>. <article-title>Functional integration of a metabolic network model and expression data without arbitrary thresholding</article-title>. <source>Bioinformatics</source>. <year>2011</year> Feb 15;<volume>27</volume>(<issue>4</issue>):<fpage>541</fpage>&#x2013;<lpage>7</lpage>.</mixed-citation></ref>
<ref id="c41"><label>41.</label><mixed-citation publication-type="journal"><string-name><surname>Orth</surname> <given-names>JD</given-names></string-name>, <string-name><surname>Thiele</surname> <given-names>I</given-names></string-name>, <string-name><surname>Palsson</surname> <given-names>B&#x00D8;</given-names></string-name>. <article-title>What is flux balance analysis</article-title>? <source>Nat Biotechnol</source>. <year>2010</year> Mar;<volume>28</volume>(<issue>3</issue>):<fpage>245</fpage>&#x2013;<lpage>8</lpage>.</mixed-citation></ref>
<ref id="c42"><label>42.</label><mixed-citation publication-type="journal"><string-name><surname>Gudmundsson</surname> <given-names>S</given-names></string-name>, <string-name><surname>Thiele</surname> <given-names>I</given-names></string-name>. <article-title>Computationally efficient flux variability analysis</article-title>. <source>BMC Bioinformatics</source>. <year>2010</year> Sep 29;<volume>11</volume>:<fpage>489</fpage>.</mixed-citation></ref>
<ref id="c43"><label>43.</label><mixed-citation publication-type="journal"><string-name><surname>Becker</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Feist</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Mo</surname> <given-names>ML</given-names></string-name>, <string-name><surname>Hannum</surname> <given-names>G</given-names></string-name>, <string-name><surname>Palsson</surname> <given-names>B&#x00D8;</given-names></string-name>, <string-name><surname>Herrgard</surname> <given-names>MJ</given-names></string-name>. <article-title>Quantitative prediction of cellular metabolism with constraint-based models: the COBRA Toolbox</article-title>. <source>Nat Protoc</source>. <year>2007</year>;<volume>2</volume>(<issue>3</issue>):<fpage>727</fpage>&#x2013;<lpage>38</lpage>.</mixed-citation></ref>
<ref id="c44"><label>44.</label><mixed-citation publication-type="journal"><string-name><surname>Foth</surname> <given-names>BJ</given-names></string-name>, <string-name><surname>Stimmler</surname> <given-names>LM</given-names></string-name>, <string-name><surname>Handman</surname> <given-names>E</given-names></string-name>, <string-name><surname>Crabb</surname> <given-names>BS</given-names></string-name>, <string-name><surname>Hodder</surname> <given-names>AN</given-names></string-name>, <string-name><surname>McFadden</surname> <given-names>GI</given-names></string-name>. <article-title>The malaria parasite Plasmodium falciparum has only one pyruvate dehydrogenase complex, which is located in the apicoplast</article-title>. <source>Mol Microbiol</source>. <year>2005</year> Jan 1;<volume>55</volume>(<issue>1</issue>):<fpage>39</fpage>&#x2013;<lpage>53</lpage>.</mixed-citation></ref>
<ref id="c45"><label>45.</label><mixed-citation publication-type="journal"><string-name><surname>Oppenheim</surname> <given-names>RD</given-names></string-name>, <string-name><surname>Creek</surname> <given-names>DJ</given-names></string-name>, <string-name><surname>Macrae</surname> <given-names>JI</given-names></string-name>, <string-name><surname>Modrzynska</surname> <given-names>KK</given-names></string-name>, <string-name><surname>Pino</surname> <given-names>P</given-names></string-name>, <string-name><surname>Limenitakis</surname> <given-names>J</given-names></string-name>, <etal>et al.</etal> <article-title>BCKDH: The Missing Link in Apicomplexan Mitochondrial Metabolism Is Required for Full Virulence of Toxoplasma gondii and Plasmodium berghei</article-title>. <source>PLOS Pathog</source>. <year>2014</year> Jul 17;<volume>10</volume>(<issue>7</issue>):<fpage>e1004263</fpage>.</mixed-citation></ref>
<ref id="c46"><label>46.</label><mixed-citation publication-type="journal"><string-name><surname>McMillan</surname> <given-names>PJ</given-names></string-name>, <string-name><surname>Stimmler</surname> <given-names>LM</given-names></string-name>, <string-name><surname>Foth</surname> <given-names>BJ</given-names></string-name>, <string-name><surname>McFadden</surname> <given-names>GI</given-names></string-name>, <string-name><surname>M&#x00FC;ller</surname> <given-names>S</given-names></string-name>. <article-title>The human malaria parasite Plasmodium falciparum possesses two distinct dihydrolipoamide dehydrogenases</article-title>. <source>Mol Microbiol</source>. <year>2005</year> Jan;<volume>55</volume>(<issue>1</issue>):<fpage>27</fpage>&#x2013;<lpage>38</lpage>.</mixed-citation></ref>
<ref id="c47"><label>47.</label><mixed-citation publication-type="journal"><string-name><surname>Goswami</surname> <given-names>AM</given-names></string-name>. <article-title>Computational analysis, structural modeling and ligand binding site prediction of Plasmodium falciparum 1-deoxy-d-xylulose-5-phosphate synthase</article-title>. <source>Comput Biol Chem</source>. <year>2017</year> Feb;<volume>66</volume>:<fpage>1</fpage>&#x2013;<lpage>10</lpage>.</mixed-citation></ref>
<ref id="c48"><label>48.</label><mixed-citation publication-type="journal"><string-name><surname>Joshi</surname> <given-names>S</given-names></string-name>, <string-name><surname>Singh</surname> <given-names>AR</given-names></string-name>, <string-name><surname>Kumar</surname> <given-names>A</given-names></string-name>, <string-name><surname>Misra</surname> <given-names>PC</given-names></string-name>, <string-name><surname>Siddiqi</surname> <given-names>MI</given-names></string-name>, <string-name><surname>Saxena</surname> <given-names>JK</given-names></string-name>. <article-title>Molecular cloning and characterization of Plasmodium falciparum transketolase</article-title>. <source>Mol Biochem Parasitol</source>. <year>2008</year> Jul;<volume>160</volume>(<issue>1</issue>):<fpage>32</fpage>&#x2013;<lpage>41</lpage>.</mixed-citation></ref>
<ref id="c49"><label>49.</label><mixed-citation publication-type="journal"><string-name><surname>Yayon</surname> <given-names>A</given-names></string-name>, <string-name><surname>Vande Waa</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Yayon</surname> <given-names>M</given-names></string-name>, <string-name><surname>Geary</surname> <given-names>TG</given-names></string-name>, <string-name><surname>Jensen</surname> <given-names>JB</given-names></string-name>. <article-title>Stage-dependent effects of chloroquine on Plasmodium falciparum in vitro</article-title>. <source>J Protozool</source>. <year>1983</year> Nov;<volume>30</volume>(<issue>4</issue>):<fpage>642</fpage>&#x2013;<lpage>7</lpage>.</mixed-citation></ref>
<ref id="c50"><label>50.</label><mixed-citation publication-type="journal"><string-name><surname>Foote</surname> <given-names>SJ</given-names></string-name>, <string-name><surname>Kyle</surname> <given-names>DE</given-names></string-name>, <string-name><surname>Martin</surname> <given-names>RK</given-names></string-name>, <string-name><surname>Oduola</surname> <given-names>AMJ</given-names></string-name>, <string-name><surname>Forsyth</surname> <given-names>K</given-names></string-name>, <string-name><surname>Kemp</surname> <given-names>DJ</given-names></string-name>, <etal>et al.</etal> <article-title>Several alleles of the multidrug-resistance gene are closely linked to chloroquine resistance in Plasmodium falciparum</article-title>. <source>Nature</source>. <year>1990</year> May;<volume>345</volume>(<issue>6272</issue>):<fpage>255</fpage>&#x2013;<lpage>8</lpage>.</mixed-citation></ref>
<ref id="c51"><label>51.</label><mixed-citation publication-type="journal"><string-name><surname>Sidhu</surname> <given-names>ABS</given-names></string-name>, <string-name><surname>Verdier-Pinard</surname> <given-names>D</given-names></string-name>, <string-name><surname>Fidock</surname> <given-names>DA</given-names></string-name>. <article-title>Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations</article-title>. <source>Science</source>. <year>2002</year> Oct 4;<volume>298</volume>(<issue>5591</issue>):<fpage>210</fpage>&#x2013;<lpage>3</lpage>.</mixed-citation></ref>
<ref id="c52"><label>52.</label><mixed-citation publication-type="journal"><string-name><surname>Egan</surname> <given-names>TJ</given-names></string-name>. <article-title>Haemozoin formation</article-title>. <source>Mol Biochem Parasitol</source>. <year>2008</year> Feb 1;<volume>157</volume>(<issue>2</issue>): <fpage>127</fpage>&#x2013;<lpage>36</lpage>.</mixed-citation></ref>
<ref id="c53"><label>53.</label><mixed-citation publication-type="journal"><string-name><surname>Pisciotta</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Coppens</surname> <given-names>I</given-names></string-name>, <string-name><surname>Tripathi</surname> <given-names>AK</given-names></string-name>, <string-name><surname>Scholl</surname> <given-names>PF</given-names></string-name>, <string-name><surname>Shuman</surname> <given-names>J</given-names></string-name>, <string-name><surname>Bajad</surname> <given-names>S</given-names></string-name>, <etal>et al.</etal> <article-title>The role of neutral lipid nanospheres in Plasmodium falciparum haem crystallization</article-title>. <source>Biochem J</source>. <year>2007</year> Feb 15;<volume>402</volume>(<issue>Pt 1</issue>): <fpage>197</fpage>&#x2013;<lpage>204</lpage>.</mixed-citation></ref>
<ref id="c54"><label>54.</label><mixed-citation publication-type="journal"><string-name><surname>Dubois</surname> <given-names>VL</given-names></string-name>, <string-name><surname>Platel</surname> <given-names>DF</given-names></string-name>, <string-name><surname>Pauly</surname> <given-names>G</given-names></string-name>, <string-name><surname>Tribouley-Duret</surname> <given-names>J</given-names></string-name>. <article-title>Plasmodium berghei: implication of intracellular glutathione and its related enzyme in chloroquine resistance in vivo</article-title>. <source>Exp Parasitol</source>. <year>1995</year> Aug;<volume>81</volume>(<issue>1</issue>):<fpage>117</fpage>&#x2013;<lpage>24</lpage>.</mixed-citation></ref>
<ref id="c55"><label>55.</label><mixed-citation publication-type="journal"><string-name><surname>Platel</surname> <given-names>DF</given-names></string-name>, <string-name><surname>Mangou</surname> <given-names>F</given-names></string-name>, <string-name><surname>Tribouley-Duret</surname> <given-names>J</given-names></string-name>. <article-title>Role of glutathione in the detoxification of ferriprotoporphyrin IX in chloroquine resistant Plasmodium berghei</article-title>. <source>Mol Biochem Parasitol</source>. <year>1999</year> Jan 25;<volume>98</volume>(<issue>2</issue>):<fpage>215</fpage>&#x2013;<lpage>23</lpage>.</mixed-citation></ref>
<ref id="c56"><label>56.</label><mixed-citation publication-type="journal"><string-name><surname>Meierjohann</surname> <given-names>S</given-names></string-name>, <string-name><surname>Walter</surname> <given-names>RD</given-names></string-name>, <string-name><surname>M&#x00FC;ller</surname> <given-names>S</given-names></string-name>. <article-title>Regulation of intracellular glutathione levels in erythrocytes infected with chloroquine-sensitive and chloroquine-resistant Plasmodium falciparum</article-title>. <source>Biochem J</source>. <year>2002</year> Dec 15;<volume>368</volume>(<issue>3</issue>):<fpage>761</fpage>&#x2013;<lpage>8</lpage>.</mixed-citation></ref>
<ref id="c57"><label>57.</label><mixed-citation publication-type="journal"><string-name><surname>Famin</surname> <given-names>O</given-names></string-name>, <string-name><surname>Krugliak</surname> <given-names>M</given-names></string-name>, <string-name><surname>Ginsburg</surname> <given-names>H</given-names></string-name>. <article-title>Kinetics of inhibition of glutathione-mediated degradation of ferriprotoporphyrin IX by antimalarial drugs</article-title>. <source>Biochem Pharmacol</source>. <year>1999</year> Jul 1;<volume>58</volume>(<issue>1</issue>):<fpage>59</fpage>&#x2013;<lpage>68</lpage>.</mixed-citation></ref>
<ref id="c58"><label>58.</label><mixed-citation publication-type="journal"><string-name><surname>Bustos</surname> <given-names>DG</given-names></string-name>, <string-name><surname>Canfield</surname> <given-names>CJ</given-names></string-name>, <string-name><surname>Canete-Miguel</surname> <given-names>E</given-names></string-name>, <string-name><surname>Hutchinson</surname> <given-names>DB</given-names></string-name>. <article-title>Atovaquone-proguanil compared with chloroquine and chloroquine-sulfadoxine-pyrimethamine for treatment of acute Plasmodium falciparum malaria in the Philippines</article-title>. <source>J Infect Dis</source>. <year>1999</year> Jun;<volume>179</volume>(<issue>6</issue>): <fpage>1587</fpage>&#x2013;<lpage>90</lpage>.</mixed-citation></ref>
<ref id="c59"><label>59.</label><mixed-citation publication-type="journal"><string-name><surname>Hallett</surname> <given-names>RL</given-names></string-name>, <string-name><surname>Dunyo</surname> <given-names>S</given-names></string-name>, <string-name><surname>Ord</surname> <given-names>R</given-names></string-name>, <string-name><surname>Jawara</surname> <given-names>M</given-names></string-name>, <string-name><surname>Pinder</surname> <given-names>M</given-names></string-name>, <string-name><surname>Randall</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal> <article-title>Chloroquine/sulphadoxine-pyrimethamine for gambian children with malaria: transmission to mosquitoes of multidrug-resistant Plasmodium falciparum</article-title>. <source>PLoS Clin Trials</source>. <year>2006</year> Jul 21;<volume>1</volume>(<issue>3</issue>):<fpage>e15</fpage>.</mixed-citation></ref>
<ref id="c60"><label>60.</label><mixed-citation publication-type="journal"><string-name><surname>Menard</surname> <given-names>D</given-names></string-name>, <string-name><surname>Madji</surname> <given-names>N</given-names></string-name>, <string-name><surname>Manirakiza</surname> <given-names>A</given-names></string-name>, <string-name><surname>Djalle</surname> <given-names>D</given-names></string-name>, <string-name><surname>Koula</surname> <given-names>MR</given-names></string-name>, <string-name><surname>Talarmin</surname> <given-names>A</given-names></string-name>. <article-title>Efficacy of chloroquine, amodiaquine, sulfadoxine-pyrimethamine, chloroquine-sulfadoxine-pyrimethamine combination, and amodiaquine-sulfadoxine-pyrimethamine combination in Central African children with noncomplicated malaria</article-title>. <source>Am J Trop Med Hyg</source>. <year>2005</year> May;<volume>72</volume>(<issue>5</issue>):<fpage>581</fpage>&#x2013;<lpage>5</lpage>.</mixed-citation></ref>
<ref id="c61"><label>61.</label><mixed-citation publication-type="journal"><string-name><surname>Vial</surname> <given-names>HJ</given-names></string-name>, <string-name><surname>Philippot</surname> <given-names>JR</given-names></string-name>, <string-name><surname>Wallach</surname> <given-names>DFH</given-names></string-name>. <article-title>A reevaluation of the status of cholesterol in erythrocytes infected by Plasmodium knowlesi and P. falciparum</article-title>. <source>Mol Biochem Parasitol</source>. <year>1984</year> Sep 1;<volume>13</volume>(<issue>1</issue>):<fpage>53</fpage>&#x2013;<lpage>65</lpage>.</mixed-citation></ref>
<ref id="c62"><label>62.</label><mixed-citation publication-type="journal"><string-name><surname>Grellier</surname> <given-names>P</given-names></string-name>, <string-name><surname>Valentin</surname> <given-names>A</given-names></string-name>, <string-name><surname>Millerioux</surname> <given-names>V</given-names></string-name>, <string-name><surname>Schrevel</surname> <given-names>J</given-names></string-name>, <string-name><surname>Rigomier</surname> <given-names>D</given-names></string-name>. <article-title>3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors lovastatin and simvastatin inhibit in vitro development of Plasmodium falciparum and Babesia divergens in human erythrocytes</article-title>. <source>Antimicrob Agents Chemother</source>. <year>1994</year> May 1;<volume>38</volume>(<issue>5</issue>):<fpage>1144</fpage>&#x2013;<lpage>8</lpage>.</mixed-citation></ref>
<ref id="c63"><label>63.</label><mixed-citation publication-type="journal"><string-name><surname>Jomaa</surname> <given-names>H</given-names></string-name>, <string-name><surname>Wiesner</surname> <given-names>J</given-names></string-name>, <string-name><surname>Sanderbrand</surname> <given-names>S</given-names></string-name>, <string-name><surname>Altincicek</surname> <given-names>B</given-names></string-name>, <string-name><surname>Weidemeyer</surname> <given-names>C</given-names></string-name>, <string-name><surname>Hintz</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal> <article-title>Inhibitors of the Nonmevalonate Pathway of Isoprenoid Biosynthesis as Antimalarial Drugs</article-title>. <source>Science</source>. <year>1999</year> Sep 3;<volume>285</volume>(<issue>5433</issue>): <fpage>1573</fpage>&#x2013;<lpage>6</lpage>.</mixed-citation></ref>
<ref id="c64"><label>64.</label><mixed-citation publication-type="journal"><string-name><surname>Ginsburg</surname> <given-names>H</given-names></string-name>. <article-title>Progress in in silico functional genomics: the malaria Metabolic Pathways database</article-title>. <source>Trends Parasitol</source>. <year>2006</year> Jun 1;<volume>22</volume>(<issue>6</issue>):<fpage>238</fpage>&#x2013;<lpage>40</lpage>.</mixed-citation></ref>
<ref id="c65"><label>65.</label><mixed-citation publication-type="journal"><string-name><surname>Tahar</surname> <given-names>R</given-names></string-name>, <string-name><surname>Basco</surname> <given-names>LK</given-names></string-name>. <article-title>Molecular Epidemiology of Malaria in Cameroon. XXV. In Vitro Activity of Fosmidomycin and its Derivatives against Fresh Clinical Isolates of Plasmodium falciparum and Sequence Analysis of 1-Deoxy-D-Xylulose 5-Phosphate Reductoisomerase</article-title>. <source>Am J Trop Med Hyg</source>. <year>2007</year> Aug 1;<volume>77</volume>(<issue>2</issue>):<fpage>214</fpage>&#x2013;<lpage>20</lpage>.</mixed-citation></ref>
<ref id="c66"><label>66.</label><mixed-citation publication-type="journal"><string-name><surname>Wiesner</surname> <given-names>J</given-names></string-name>, <string-name><surname>Henschker</surname> <given-names>D</given-names></string-name>, <string-name><surname>Hutchinson</surname> <given-names>DB</given-names></string-name>, <string-name><surname>Beck</surname> <given-names>E</given-names></string-name>, <string-name><surname>Jomaa</surname> <given-names>H</given-names></string-name>. <article-title>In vitro and in vivo synergy of fosmidomycin, a novel antimalarial drug, with clindamycin</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2002</year> Sep;<volume>46</volume>(<issue>9</issue>) : <fpage>2889</fpage>&#x2013;<lpage>94</lpage>.</mixed-citation></ref>
</ref-list>
<sec id="s6" sec-type="supplementary-material"><title>Supplemental Information</title>
<table-wrap id="tblS1" orientation="portrait" position="float">
<label>Suppl. Table 1:</label>
<caption><title>Reactions modified to curate the <italic>Plasmodium falciparum</italic> genome-scale metabolic model.</title></caption>
<graphic xlink:href="428284_tblS1.tif"/>
<graphic xlink:href="428284_tblS1a.tif"/>
</table-wrap>
<table-wrap id="tblS2" orientation="portrait" position="float">
<label>Suppl. Table 2:</label>
<caption><title>Down-regulated Differentially Expressed Genes in (A) Short and (B) Long-term Chloroquine-treated Parasites.</title></caption>
<graphic xlink:href="428284_tblS2A.tif"/>
<graphic xlink:href="428284_tblS2Aa.tif"/>
<graphic xlink:href="428284_tblS2Ab.tif"/>
<graphic xlink:href="428284_tblS2B.tif"/>
<graphic xlink:href="428284_tblS2Ba.tif"/>
<graphic xlink:href="428284_tblS2Bc.tif"/>
<graphic xlink:href="428284_tblS2Bd.tif"/>
</table-wrap>
<table-wrap id="tblS3" orientation="portrait" position="float">
<label>Suppl. Table 3:</label>
<caption><title>Up-regulated Differentially Expressed Genes in (A) Short and (B) Long-term Chloroquine-treated Parasites.</title></caption>
<graphic xlink:href="428284_tblS3A.tif"/>
<graphic xlink:href="428284_tblS3Aa.tif"/>
<graphic xlink:href="428284_tblS3B.tif"/>
</table-wrap>
<table-wrap id="tblS4" orientation="portrait" position="float">
<label>Suppl. Table 4:</label>
<caption><title>Significant Down Regulation of Metabolic Genes Arising from Chloroquine Treatment.</title></caption>
<graphic xlink:href="428284_tblS4A.tif"/>
<graphic xlink:href="428284_tblS4Aa.tif"/>
<graphic xlink:href="428284_tblS4B.tif"/>
<graphic xlink:href="428284_tblS4C.tif"/>
</table-wrap>
<table-wrap id="tblS5" orientation="portrait" position="float">
<label>Suppl. Table 5.</label>
<caption><title>Reactions Essential in only Chloroquine-Treated Models.</title></caption>
<graphic xlink:href="428284_tblS5.tif"/>
<graphic xlink:href="428284_tblS5a.tif"/>
<graphic xlink:href="428284_tblS5b.tif"/>
<graphic xlink:href="428284_tblS5c.tif"/>
</table-wrap>
<table-wrap id="tblS6" orientation="portrait" position="float">
<label>Suppl. Table 6.</label>
<caption><title>Reactions Essential in only the Short-Term Treatment Condition.</title></caption>
<graphic xlink:href="428284_tblS6.tif"/>
</table-wrap>
<table-wrap id="tblS7" orientation="portrait" position="float">
<label>Suppl. Table 7.</label>
<caption><title>Reactions Essential in only the Long-Term Treatment Condition.</title></caption>
<graphic xlink:href="428284_tblS7.tif"/>
</table-wrap>
<table-wrap id="tblS8" orientation="portrait" position="float">
<label>Suppl. Table 8.</label>
<caption><title>Flux Values for Isoprenoid Metabolism Reactions in the Chloroquine-treated and Untreated Models.</title></caption>
<graphic xlink:href="428284_tblS8.tif"/>
<graphic xlink:href="428284_tblS8a.tif"/>
</table-wrap>
<table-wrap id="tblS9" orientation="portrait" position="float">
<label>Suppl. Table 9.</label>
<caption><title>Flux Values for Folate Metabolism Reactions in the Chloroquine-treated and Untreated Models.</title></caption>
<graphic xlink:href="428284_tblS9.tif"/>
<graphic xlink:href="428284_tblS9a.tif"/>
</table-wrap></sec>
<sec>
<title>Ethics approval and consent to participate</title>
<p>Not applicable.</p></sec>
<sec>
<title>Consent for publication</title>
<p>Not applicable.</p></sec>
<sec sec-type="availability">
<title>Availability of data and materials:</title>
<p>The publically available dataset analyzed during the current study are available on the NCBI&#x2019;s Gene Expression Omnibus, GSE31109. Additionally, our curated model and code are available on GitHub, at <ext-link ext-link-type="uri" xlink:href="https://github.com/anauntaroiu/Chloroquine-Project">https://github.com/anauntaroiu/Chloroquine-Project</ext-link>.</p></sec>
<sec sec-type="COI-statement">
<title>Competing interests</title>
<p>The authors declare that they have no competing interests.</p></sec>
<sec>
<title>Funding</title>
<p>The study was financed by the National Institute of Allergy and Infectious Disease (R21AI119881 - JG and JP), an institutional training grant (T32GM008136 - MC), and the Arnold and Mabel Beckman Foundation (via the Beckman Scholars program - AU).</p></sec>
<sec>
<title>Authors&#x2019; contributions</title>
<p>AU and MC designed the study. AU curated the model and performed statistical and network analyses. AU and MC interpreted the data and analyses. AU wrote the manuscript. MC, JG, and JP edited the manuscript. JG and JP provided resources. All authors read and approved the final manuscript.</p></sec>
<ack><title>Acknowledgements</title>
<p>We thank the members of the Guler and Papin labs for their thoughtful feedback and the openCobra community for software development integral to this work.</p>
</ack>
</back>
</article>